The therapy, indicated for adults with obesity or those who are overweight with weight-related conditions, will be available starting at $149 per month for the lowest dose under Ros cash-pay model, excluding membership fees
Semaglutide not only consistently reduces energy intake (Blundell et al., 2017) but also achieves substantial weight loss, up to approximately 15% in individuals who are overweight or obese (Wilding et al., 2021)
Providers assess baseline cardiovascular health, kidney function, diabetes status, and BMI history
Structural modifications extend its working window in research settings
Even FDA-approved patches that effectively deliver medication unlike the GLP-1 patches can cause skin irritation both from the medications and also from the patches themselves, Jay says
We use third-party-tested peptides from trusted California labs and provide full administration kits and hands-on support to ensure safe, confident treatment